X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, the intellectual property covers the use of emricasan, an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, for the treatment of disease in humans resulting from viral or bacterial infections.
Lead Product(s): Emricasan
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johns Hopkins University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 03, 2023
Details:
CTS-2090 is a pan-caspase and caspase selective inhibitor that protect the body’s natural process to restore immune function. It has provided protection against inflammation-driven damage to the lining of the GI tract and also protected against loss of body weight.
Lead Product(s): CTS-2090
Therapeutic Area: Infections and Infectious Diseases Product Name: CTS-2090
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
U.S. FDA has verbally notified the company that it has additional questions about the company’s IND application package for the planned Phase 1/2 clinical trial of HST-003.
Lead Product(s): HST-003
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: HST-003
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
Histogen will retain ownership and oversight over emricasan and responsibility for all regulatory filings and maintaining its existing caspase inhibitor patent portfolio. Amerimmune will lead development efforts of emricasan in a phase 1 study in mild-COVID-19 patients.
Lead Product(s): Emricasan
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Amerimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 27, 2020
Details:
This blinded, randomized, placebo controlled, single site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST-001 to placebo.
Lead Product(s): HST-001
Therapeutic Area: Dermatology Product Name: HST-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Histogen received communications from the Office of Combination Products that HST-002 is a drug-biologic-device combination product. HST-001 1b/2a trial for androgenic alopecia in men on track for top line data results in 4Q20.
Lead Product(s): HST-002
Therapeutic Area: Dermatology Product Name: HST-002
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The funding supports Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee led by Histogen. The trial is designed to evaluate HST-003 in combination with a microfracture procedure to treat recent focal cartilage defects in the knee caused by injury.
Lead Product(s): HST-003
Therapeutic Area: Musculoskeletal Product Name: HST-003
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2020
Details:
This blinded, randomized, placebo controlled, single site study is designed to assess the safety and tolerability of HST 001, and indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.
Lead Product(s): HST 001
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
This merger is transformative for Histogen as it looks to advance its novel regenerative medicine pipeline. The merger provides an opportunity for Histogen to become a leader in the aesthetics and orthopedic medicine markets.
Lead Product(s): HST 001
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Conatus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 27, 2020
Details:
Clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the ASCO 2020.
Lead Product(s): HST 004
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
